- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02209714
Safety, Tolerability and Pharmacodynamics After Oral Administration of BIIF 1149 BS in Healthy Male Volunteers
August 5, 2014 updated by: Boehringer Ingelheim
A Single Increasing Dose Safety, Tolerability and Pharmacodynamics (Citric Acid Challenge) Study After Oral Administration of BIIF 1149 BS (Single Doses as Tablets: 40, 65, 100 mg) in Healthy Male Volunteers (Randomised, Double-blind Within Each Dose Group, Placebo-controlled, Parallel Groups)
The objective of the study is to obtain information about the safety and tolerability of BIIF 1149 BS45 (single dose: 40, 65, 100 mg), to determine the pharmacologically active dose (range) by performing a citric acid challenge test and to obtain preliminary pharmacokinetic data.
Study Overview
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy males, based on a complete medical examination
- Age range from 21 to 50 years
- +/- 20 % of their normal weight (Broca-Index)
- Written informed consent
Exclusion Criteria:
- Volunteers will be excluded from the study if the results of the medical examination or laboratory tests are judged by the clinical investigator to differ significantly from normal clinical values
- Volunteers with known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Volunteers with diseases of the central nervous system (such as epilepsy) or with psychiatric disorders
- Volunteers with known history of orthostatic hypotension, fainting spells or blackouts
- Volunteers with chronic or relevant acute infections (especially respiratory infections, cough)
- Volunteers with history of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- Volunteers who have taken a drug with a long half-life (≥ 24 hours) within ten half-lives of the respective drug before enrolment in the study
- Volunteers who received any other drugs which might influence the results of the study during the week prior to the start of the study
- Volunteers who have participated in another study with an investigational drug within the last 2 months preceding this study
- Volunteers who smoke more than 10 cigarettes (or equivalent) per day
- Volunteers who are not able to refrain from smoking on study days
- Volunteers who drink more than 40 g of alcohol per day
- Volunteers who are dependent on drugs
- Volunteers who are participated in excessive physical activities (e.g. competitive sports) during the last week before the study
- Volunteers who have donated blood (≥ 100 ml) within the last four weeks
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Experimental: BIIF 1149 BS
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients with adverse events
Time Frame: up to 8 days after last drug administration
|
up to 8 days after last drug administration
|
Number of patients with clinically relevant changes in vital functions (blood pressure, pulse rate)
Time Frame: up to 8 days after last drug administration
|
up to 8 days after last drug administration
|
Number of patients with clinically relevant changes in electrocardiogram (ECG)
Time Frame: up to 8 days after last drug administration
|
up to 8 days after last drug administration
|
Number of patients with clinically relevant changes in laboratory parameters
Time Frame: up to 8 days after last drug administration
|
up to 8 days after last drug administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum drug plasma concentration (Cmax)
Time Frame: up to 360 hours after drug administration
|
up to 360 hours after drug administration
|
|
Time to reach maximum drug concentration (tmax)
Time Frame: up to 360 hours after drug administration
|
up to 360 hours after drug administration
|
|
Total area under the plasma drug concentration-time curve (AUC) for several time points
Time Frame: up to 360 hours after drug administration
|
up to 360 hours after drug administration
|
|
Terminal half-life (t1/2)
Time Frame: up to 360 hours after drug administration
|
up to 360 hours after drug administration
|
|
Mean residence time (MRT)
Time Frame: up to 360 hours after drug administration
|
up to 360 hours after drug administration
|
|
Total clearance after oral administration (CLtot/f)
Time Frame: up to 360 hours after drug administration
|
up to 360 hours after drug administration
|
|
Amount of drug excreted in urine (Ae)
Time Frame: up to 360 hours after drug administration
|
up to 360 hours after drug administration
|
|
Measurement of pharmacodynamic activity
Time Frame: Screening, at least 15 days after first administration
|
Citric acid challenge
|
Screening, at least 15 days after first administration
|
Volume of Distribution during terminal phase after oral administration (Vz/F)
Time Frame: up to 360 hours after drug administration
|
up to 360 hours after drug administration
|
|
Renal clearance in the time interval form 0 to x h (Clren0-xh)
Time Frame: up to 360 hours after drug administration
|
up to 360 hours after drug administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 1999
Primary Completion (Actual)
February 1, 2000
Study Registration Dates
First Submitted
August 5, 2014
First Submitted That Met QC Criteria
August 5, 2014
First Posted (Estimate)
August 6, 2014
Study Record Updates
Last Update Posted (Estimate)
August 6, 2014
Last Update Submitted That Met QC Criteria
August 5, 2014
Last Verified
August 1, 2014
More Information
Terms related to this study
Other Study ID Numbers
- 1157.4
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States